Cargando…
Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
PURPOSE: A new fixed-dose combination (FDC) formulation of 120 mg fimasartan and 20 mg rosuvastatin was developed to increase therapeutic convenience and improve treatment compliance. METHODS: A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 7-day washout period w...
Autores principales: | Kang, Woo Youl, Seong, Sook Jin, Ohk, Boram, Gwon, Mi-Ri, Kim, Bo Kyung, Cho, Seungil, Shim, Wang-Seob, Lee, Kyung-Tae, Kim, Eun Hee, Yang, Dong Heon, Lee, Hae Won, Yoon, Young-Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208487/ https://www.ncbi.nlm.nih.gov/pubmed/30464392 http://dx.doi.org/10.2147/DDDT.S161917 |
Ejemplares similares
-
A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020) -
The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017) -
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
por: Lee, Jieon, et al.
Publicado: (2018) -
Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects
por: Oh, Minkyung, et al.
Publicado: (2018) -
A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)